{
    "nct_id": "NCT05451771",
    "official_title": "An Open-label Phase I/II Trial of Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Systemic Light-Chain Amyloidosis",
    "inclusion_criteria": "* Age ≥ 18 years at time of signing Informed Consent Form\n* Ability to comply with the study protocol, in the investigator's judgment\n* Confirmed diagnosis of systemic AL amyloidosis by mass spectrometry or immunohistochemistry (IHC) on a tissue biopsy\n* Has received ≥1 prior lines of therapy, including an anti-cluster of differentiation 38 (CD 38) monoclonal antibody\n* Participants with a history of autologous hematopoietic cell transplantation must have recovered from any transplant-related toxicities\n* Presence of t(11;14) on FISH at any time since diagnosis (Eligibility must confirmed by FISH testing at Columbia University Irving Medical Center (CUIMC)\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Known hypersensitivity to any of the study drugs\n* History of other malignancy that could affect compliance with the protocol or interpretation of results (Patients with a history of curatively treated basal or squamous cell carcinoma of the skin, in situ carcinoma of the cervix, breast cancer, or Hodgkin's Lymphoma are generally eligible. Patients with a malignancy that has been treated, but not with curative intent, will be excluded, unless the malignancy has been in remission without treatment for ≥ 2 years prior to enrollment.)\n* Evidence of other clinically significant uncontrolled condition(s) including, but not limited to, uncontrolled systemic infection (viral, bacterial, or fungal)\n* Patients on renal replacement therapy\n* Known GI disease or GI procedure that could interfere with oral absorption (including difficulty swallowing)\n* New York Heart Association (NYHA) Class III or IV heart failure\n* Mayo stage three-B (IIIB) with N-terminal pro-hormone B-type natriuretic peptide (NT-Pro BNP) > 8500 pg/mL\n* Prior exposure to anti-apoptotic protein B-cell lymphoma 2 (BCL-2) inhibitors\n* Patients with human immunodeficiency virus (HIV) who are not on highly active antiretroviral therapy (HAART) or those with active hepatitis A, B, or C infection\n* Patients meeting criteria for symptomatic multiple myeloma by one of the following:(a) Lytic lesions on imaging (b) Plasmacytoma, (c) Hypercalcemia without any alternate etiology, or (c) Bone marrow plasma cell infiltrate of greater than 60%",
    "miscellaneous_criteria": ""
}